Antithrombotic effect of PMC, a potent α-tocopherol analogue on platelet plug formation in vivo

G. Hsiao, M. H. Yen, Y. M. Lee, J. R. Sheu

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Platelet thrombi formation was induced by irradiation of mesenteric venules with filtered light in mice pretreated intravenously with fluorescein sodium. PMC (2,2,5,7,8-pentamethyl-6-hydroxychromane; 20 μg/g, i.v.) significantly prolonged the latent period of inducing platelet plug formation in mesenteric venules. When fluorescein sodium was given at 10 μg/kg, PMC (20 μg/g) delayed occlusion time by about 1.7-fold. Furthermore, aspirin (250 μg/g) also showed similar activity in delaying the occlusion time. On a molar basis, PMC was about 14-fold more potent than aspirin at delaying the occlusion time. PMC was also effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at doses of 5 and 10 μg/g. In addition, intravenous injection of PMC (5 μg/g) significantly prolonged bleeding time by about 1.6-fold compared with normal saline in severed mesenteric arteries of rats. Continuous infusion of PMC (1 μg/g/min) significantly increased the bleeding time by about 1.6-fold and the bleeding time was also significantly prolonged for up to 90 min after cessation of PMC infusion. These results suggest that PMC has an effective antiplatelet effect in vivo and may be a potential therapeutic agent for arterial thrombosis, but must be assessed further for toxicity.

Original languageEnglish
Pages (from-to)699-704
Number of pages6
JournalBritish Journal of Haematology
Volume117
Issue number3
DOIs
Publication statusPublished - 2002

Fingerprint

Bleeding Time
Tocopherols
Blood Platelets
Venules
Fluorescein
Aspirin
Thrombosis
Mesenteric Arteries
Pulmonary Embolism
Intravenous Injections
Adenosine Diphosphate
Light
Mortality
Therapeutics

Keywords

  • Arterial thrombosis
  • Fluorescein sodium
  • Occlusion time
  • Platelet plug
  • PMC

ASJC Scopus subject areas

  • Hematology

Cite this

Antithrombotic effect of PMC, a potent α-tocopherol analogue on platelet plug formation in vivo. / Hsiao, G.; Yen, M. H.; Lee, Y. M.; Sheu, J. R.

In: British Journal of Haematology, Vol. 117, No. 3, 2002, p. 699-704.

Research output: Contribution to journalArticle

@article{f2da06e7cc374ae09ff111f7efb2dcc1,
title = "Antithrombotic effect of PMC, a potent α-tocopherol analogue on platelet plug formation in vivo",
abstract = "Platelet thrombi formation was induced by irradiation of mesenteric venules with filtered light in mice pretreated intravenously with fluorescein sodium. PMC (2,2,5,7,8-pentamethyl-6-hydroxychromane; 20 μg/g, i.v.) significantly prolonged the latent period of inducing platelet plug formation in mesenteric venules. When fluorescein sodium was given at 10 μg/kg, PMC (20 μg/g) delayed occlusion time by about 1.7-fold. Furthermore, aspirin (250 μg/g) also showed similar activity in delaying the occlusion time. On a molar basis, PMC was about 14-fold more potent than aspirin at delaying the occlusion time. PMC was also effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at doses of 5 and 10 μg/g. In addition, intravenous injection of PMC (5 μg/g) significantly prolonged bleeding time by about 1.6-fold compared with normal saline in severed mesenteric arteries of rats. Continuous infusion of PMC (1 μg/g/min) significantly increased the bleeding time by about 1.6-fold and the bleeding time was also significantly prolonged for up to 90 min after cessation of PMC infusion. These results suggest that PMC has an effective antiplatelet effect in vivo and may be a potential therapeutic agent for arterial thrombosis, but must be assessed further for toxicity.",
keywords = "Arterial thrombosis, Fluorescein sodium, Occlusion time, Platelet plug, PMC",
author = "G. Hsiao and Yen, {M. H.} and Lee, {Y. M.} and Sheu, {J. R.}",
year = "2002",
doi = "10.1046/j.1365-2141.2002.03492.x",
language = "English",
volume = "117",
pages = "699--704",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Antithrombotic effect of PMC, a potent α-tocopherol analogue on platelet plug formation in vivo

AU - Hsiao, G.

AU - Yen, M. H.

AU - Lee, Y. M.

AU - Sheu, J. R.

PY - 2002

Y1 - 2002

N2 - Platelet thrombi formation was induced by irradiation of mesenteric venules with filtered light in mice pretreated intravenously with fluorescein sodium. PMC (2,2,5,7,8-pentamethyl-6-hydroxychromane; 20 μg/g, i.v.) significantly prolonged the latent period of inducing platelet plug formation in mesenteric venules. When fluorescein sodium was given at 10 μg/kg, PMC (20 μg/g) delayed occlusion time by about 1.7-fold. Furthermore, aspirin (250 μg/g) also showed similar activity in delaying the occlusion time. On a molar basis, PMC was about 14-fold more potent than aspirin at delaying the occlusion time. PMC was also effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at doses of 5 and 10 μg/g. In addition, intravenous injection of PMC (5 μg/g) significantly prolonged bleeding time by about 1.6-fold compared with normal saline in severed mesenteric arteries of rats. Continuous infusion of PMC (1 μg/g/min) significantly increased the bleeding time by about 1.6-fold and the bleeding time was also significantly prolonged for up to 90 min after cessation of PMC infusion. These results suggest that PMC has an effective antiplatelet effect in vivo and may be a potential therapeutic agent for arterial thrombosis, but must be assessed further for toxicity.

AB - Platelet thrombi formation was induced by irradiation of mesenteric venules with filtered light in mice pretreated intravenously with fluorescein sodium. PMC (2,2,5,7,8-pentamethyl-6-hydroxychromane; 20 μg/g, i.v.) significantly prolonged the latent period of inducing platelet plug formation in mesenteric venules. When fluorescein sodium was given at 10 μg/kg, PMC (20 μg/g) delayed occlusion time by about 1.7-fold. Furthermore, aspirin (250 μg/g) also showed similar activity in delaying the occlusion time. On a molar basis, PMC was about 14-fold more potent than aspirin at delaying the occlusion time. PMC was also effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at doses of 5 and 10 μg/g. In addition, intravenous injection of PMC (5 μg/g) significantly prolonged bleeding time by about 1.6-fold compared with normal saline in severed mesenteric arteries of rats. Continuous infusion of PMC (1 μg/g/min) significantly increased the bleeding time by about 1.6-fold and the bleeding time was also significantly prolonged for up to 90 min after cessation of PMC infusion. These results suggest that PMC has an effective antiplatelet effect in vivo and may be a potential therapeutic agent for arterial thrombosis, but must be assessed further for toxicity.

KW - Arterial thrombosis

KW - Fluorescein sodium

KW - Occlusion time

KW - Platelet plug

KW - PMC

UR - http://www.scopus.com/inward/record.url?scp=0036105442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036105442&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2002.03492.x

DO - 10.1046/j.1365-2141.2002.03492.x

M3 - Article

VL - 117

SP - 699

EP - 704

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 3

ER -